The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
Open accessAbstract
In multiple sclerosis (MS), B cell–depleting therapy using monoclonal anti-CD20 Abs, including rituximab (RTX) and ocrelizumab, effectively reduces disease activity. Based on indirect evidence, it is generally believed that elimination of the Ag-presenting capabilities and Ag nonspecific immune functions of B cells underlie the therapeutic efficacy. However, a small subset of T lymphocytes (T cells) was shown to also express CD20, but controversy prevails surrounding the true existence of this T cell subpopulation. Using single-cell imaging flow cytometry and expression profiling of sorted lymphocyte subsets, we unequivocally demonstrate the existence of CD3+CD20dim T cells. We show that in MS patients, increased levels of CD3+CD20dim T cells are effectively depleted by RTX. The pathological relevance of this T cell subset in MS remains to be determined. However, given their potential proinflammatory functionality, depletion of CD20-expressing T cells may also contribute to the therapeutic effect of RTX and other mAbs targeting CD20.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationImmunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
A framework for oligonucleotide microarray preprocessing
Carvalho, B. S., & Irizarry, R. A. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq431 · Cited by 1,550
Babbe, H., Roers, A., Waisman, A., Lassmann, H., Goebels, N., Hohlfeld, R., Friese, M., Schröder, R., Deckert, M., Schmidt, S., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.3.393 · Cited by 951
arrayQualityMetrics—a bioconductor package for quality assessment of microarray data
Kauffmann, A., Gentleman, R., & Huber, W. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btn647 · Cited by 946 · cited 1×
“Quality of the analyzed arrays was ascertained using the arrayQualityMetrics package (10).”
MethodMaloney, D., Liles, T., Czerwinski, D., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994) · Blood · doi:10.1182/blood.v84.8.2457.2457 · Cited by 762
Kappos, L., Li, D., Calabresi, P. A., O'Connor, P., Bar-Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61649-8 · Cited by 743
Self-citationWei, C., Anolik, J., Cappione, A., Zheng, B., Pugh-Bernard, A., Brooks, J., Lee, E.-H., Milner, E. C. B., & Sanz, I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6624 · Cited by 604
Leandro, M. J., Cambridge, G., Ehrenstein, M. R., & Edwards, J. C. W. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21617 · Cited by 560
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial
Bar‐Or, A., Calabresi, P. A. J., Arnold, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E., Gazda, S., Fox, R. J., Panzara, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21363 · Cited by 527
Cited by
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
von Büdingen, H.-C., Palanichamy, A., Lehmann-Horn, K., Michel, B. A., & Zamvil, S. S. (2015) · European Neurology · doi:10.1159/000377675 · Cited by 1,463
Self-citationMultiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31817-3 · Cited by 756
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Apostolidis, S. A., Kakara, M., Painter, M. M., Goel, R. R., Mathew, D., Lenzi, K., Rezk, A., Patterson, K. R., Espinoza, D. A., Kadri, J. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01507-2 · Cited by 507
Reassessing B cell contributions in multiple sclerosis
Li, R., Patterson, K. R., & Bar-Or, A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0135-x · Cited by 401
B cells in autoimmune and neurodegenerative central nervous system diseases
Sabatino, J. J., Pröbstel, A.-K., & Zamvil, S. S. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0233-2 · Cited by 343
The role of TH17 cells in multiple sclerosis: Therapeutic implications
Moser, T., Akgün, K., Proschmann, U., Sellner, J., & Ziemssen, T. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102647 · Cited by 302
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
Baker, D., Marta, M., Pryce, G., Giovannoni, G., & Schmierer, K. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.01.042 · Cited by 289
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A., & Muraro, P. A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00498-5 · Cited by 271
B‐cell Therapy for Multiple Sclerosis: Entering an era
Greenfield, A. L., & Hauser, S. L. (2018) · Annals of Neurology · doi:10.1002/ana.25119 · Cited by 265
Self-citationCOVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
Baker, D., Roberts, C. A. K., Pryce, G., Kang, A. S., Marta, M., Reyes, S., Schmierer, K., Giovannoni, G., & Amor, S. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13495 · Cited by 192
Frieser, D., Pignata, A., Khajavi, L., Shlesinger, D., Gonzalez-Fierro, C., Nguyen, X.-H., Yermanos, A., Merkler, D., Höftberger, R., Desestret, V., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl6157 · Cited by 102
Metadata
- Authors
- Palanichamy, A., Jahn, S., Nickles, D., Derstine, M., Abounasr, A., Hauser, S. L., Baranzini, S. E., Leppert, D., & von Büdingen, H.-C.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-07
- Volume
- 193
- Issue
- 2
- Pages
- 580-586
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2126336004
- Cited by
- 289
- References
- 32
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.